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BACKGROUND: The Prostate Cancer Prevention Trial has shown a protective effect of finasteride on prostate cancer in low-risk men. It
is uncertain whether similar results can be expected when finasteride is used to treat benign prostatic hyperplasia.
METHODS: We performed an observational cohort study within the Finnish Prostate Cancer Screening Trial. Using a comprehensive
prescription database on medication reimbursements during 1995–2004 of men using finasteride or alpha-blockers for benign
prostatic hyperplasia, we evaluated prostate cancer incidence among 23320 men screened during 1996–2004.
RESULTS: Compared to medication non-users, overall prostate cancer incidence was not significantly affected in finasteride users
(hazard ratio 0.87; 95% CI 0.63–1.19). Incidence of Gleason 2–6 tumours, however, was decreased among finasteride users (HR
0.59; 95% CI 0.38–0.91), whereas incidence of Gleason 7–10 tumours was unchanged (HR 1.33; 95% CI 0.77–2.30). The protective
effect concerned mainly screen-detected tumours. Overall prostate cancer risk was not significantly reduced among alpha-blocker
users relative to non-users, but decreased incidence of high-grade tumours was observed (0.55; 95% CI 0.31–0.96).
CONCLUSIONS: The detection of low-grade, early-stage tumours is decreased among men who use finasteride for symptomatic BPH.
The protective effect of finasteride can also be expected in men with benign prostatic hyperplasia.
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Finasteride, a 5-alpha reductase enzyme-inhibitor that inhibits
conversion of testosterone into active androgen metabolite
dihydrotestosterone, thereby lowering prostate volume and serum
prostate-specific antigen (PSA) level (Marberger, 2006), is used for
treatment of benign prostatic hyperplasia (BPH) and male pattern
baldness. The Prostate Cancer Prevention Trial (PCPT) has
reported a 25% decrease in prostate cancer incidence in men
receiving finasteride compared with placebo (Thompson et al,
2003). The trial participants had baseline PSA 3.0ngml
 1 or less
and low symptom score of lower urinary tract symptoms (LUTS).
The restrictive inclusion criteria limit the generalisability of the
findings. It is not known whether the results are applicable to men
using finasteride for symptomatic BPH.
a1-Adrenoceptor antagonists (alpha-blockers) are used in the
medical management of symptoms of benign prostatic hyperplasia.
Alpha-blockers lower smooth muscle tension in the prostate and
urinary tract, thereby improving urinary flow and decreasing
LUTS (Ishizuka et al, 2002). Some experimental studies have
reported increased prostate cancer cell apoptosis after treatment
with quinazoline-derived alpha-blockers, terazosin and doxazosin
(Kyprianou and Benning, 2000; Benning and Kyprianou, 2002).
One cohort study has reported a decreased incidence among
alpha-blocker users (Harris et al, 2007).
We evaluated the effect of finasteride and alpha-blocker usage
on prostate cancer incidence in a cohort of men participating in
the screening arm of the Finnish Prostate Cancer Screening Trial
during 1996–2004.
MATERIALS AND METHODS
The Finnish Prostate Cancer Screening Trial is a part of the
European Randomized Study of Prostate Cancer Screening. The
trial assesses whether screening can reduce prostate cancer
mortality (Ma ¨a ¨tta ¨nen et al, 1999) The ethical committees of each
participating hospital approved the study protocol. In 1996–1999,
all men aged 55–67 years and residing in the metropolitan areas of
Helsinki and Tampere (80484 men) were identified from the
population register of Finland and randomly assigned into either
the screening arm (32000 men) or the control arm (48484 men) of
the trial. The detailed protocol has been described previously
(Ma ¨a ¨tta ¨nen et al, 1999). For exclusion of prevalent prostate cancer
cases at randomisation, the cohort was linked to the comprehen-
sive Finnish Cancer Registry (Teppo et al, 1994).
Men in the screening arm were recruited with mailed invitations
to undergo a PSA screening test at 4-year intervals. After a written
informed consent, a blood sample was drawn. All participants also
filled in a questionnaire on prostate cancer family history and
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yprevious prostatic diseases. Participants of the third screening
round were asked to provide information on height and weight
for calculation of the body mass index (BMI). The population
was linked annually to the Finnish Cancer Registry to obtain
information on cases diagnosed between the screening rounds.
During 1996–2004 two screening rounds were completed. The
third screening round was started in 2004. A total of 23320 men
(73%) had at least one PSA determination during the study period.
A total of 1594 new cases were diagnosed in the screening arm. Of
these, 1273 cases were screen detected, whereas 321 were interval
cancers. TNM stage was available for 99.6% and Gleason grade in
97.7% of the tumours.
The prescription database of the Social Insurance Institution of
Finland (SII) provided detailed information on finasteride and
alpha-blocker usage during 1995–2004 for each study participant.
SII provides reimbursements for the cost of medicines prescribed
by a physician (with the exception of hospital inpatients) to each
Finnish citizen as part of the national public health insurance
(Martikainen and Rajaniemi, 2002). All reimbursements for
purchased prescription drugs approved as reimbursable by the
SII are recorded in the reimbursement database.
All drugs in clinical use for treatment of BPH in Finland are
reimbursable and available only through a physician’s prescrip-
tion. During the study period, these included 5a-reductase inhib-
itor, finasteride, and alpha-blockers, tamsulosin (since 1996) and
alfuzosin (since 1997). Finasteride prescribed for treatment of
androgenic alopecia was not reimbursable and thus not recorded
by the prescription database.
Amount of medication use was defined as daily doses in
treatment of BPH: finasteride 5mg, tamsulosin 0.4mg and
alfuzosin 10mg per day. The cumulative number of daily doses
during the study period was calculated for each person based on
dosage, package size and number of packages bought each year.
Cumulative amounts of tamsulosin and alfuzosin use were
summed to obtain total usage of alpha-blockers.
Statistical analysis
Cox proportional hazards regression was used to estimate hazard
ratios and their 95% confidence intervals (CIs) for prostate cancer
by medication usage. Men who used neither finasteride nor alpha-
blockers were used as the reference group in all analyses on risk.
Each man in the study population contributed person time
from the date of the first screening test until date of diagnosis,
emigration from the study area, death or end of study period
(31 December 2004), whichever came first.
Time-dependent Cox regression model with adjustment for age
(continuous time-dependent covariate; Po0.001 in the model),
family history (father, brother or son diagnosed with prostate cancer;
P¼0.916), simultaneous use of the other group of BPH drugs
(P¼0.07 for finasteride or P¼0.847 for alpha-blockers), number
of PSA screens attended (continuous time-dependent covariate;
Po0.001) and the calendar period of screening test (before or after
year 2000; P¼0.209) was used for analyses. Additional adjustment
for BMI (P¼0.854) and prostate volume (as measured by a urologist
in a transrectal ultrasound examination; P¼0.047) was used in
subgroup analyses of men with this information available (3130 men
attending the third screening round in 2004). Age was the single
most influential covariate in the model.
Each man, who was not a medication user at randomisation,
contributed person time in the analysis as a non-user until the first
medication reimbursement. After a period of 6 months without
reimbursements, the men were reclassified as medication non-
users. Exposure status was allowed to change as often as necessary.
If the man had simultaneously used both finasteride and alpha-
blockers, he contributed person time (and potentially events) in
both categories, that is, as a finasteride user and as an alpha-
blocker user.
Amount (daily doses) and duration (in years) of medication use
were analysed as time-dependent covariates. In analyses strati-
fied by cumulative amount/duration of medication use, the users
contributed person time in lower stratum until reaching the cut-
point for upper stratum.
Trends in incidence by amount or duration of medication use
were tested by adding these indicators into Cox regression model
as continuous covariates.
The proportional hazards assumption was tested by adding the
interaction term for finasteride or alpha-blocker use and person
time to the model. The term was not statistically significant by the
likelihood ratio test, confirming the assumption.
All analyses were performed using SPSS 15.0 statistical software.
RESULTS
Of the 23320 men in the cohort, 1754 (7.5%) had used finasteride
and 3848 (16.5%) had used either tamsulosin or alfuzosin. Preva-
lence of medication use increased with age at start of follow-up.
Family history was comparable in the two groups (Table 1). The
age-standardised median PSA was higher among BPH medication
users compared with non-users (Table 1). Both finasteride and
alpha-blocker use was associated with a decreased proportion
of free PSA, the effect again being stronger in finasteride users.
Among the men attending the third screening round, average
prostate volumes and the median BMI were higher among
medication users than non-users (Table 1).
Overall, finasteride use was not significantly associated with risk
(HR 0.87, 95% CI 0.63–1.19; Table 2). However, the risk of low-
grade (Gleason 2–6) tumours was decreased among finasteride
users (HR 0.59; 95% CI 0.38–0.91) and further diminished in
relation to the cumulative amount and duration of medication
usage (P for trend 0.009 and 0.019, respectively; Table 2).
Generally, incidence of high-grade, organ-confined or advanced
stage tumours was not affected by finasteride usage (Table 2).
However, among long-term finasteride users, increased incidence
of high-grade tumours was observed (HR 2.49; 95% CI 1.27–4.89
for men who had used at least 1087 doses of finasteride). Overall
risk did not differ between alpha-blocker users and non-users.
However, lowered incidence of high-grade tumours was observed
(HR 0.55; 95% CI 0.31–0.96), with a decreasing trend in risk with
cumulative duration of alpha-blocker use (Table 3).
In an analysis stratified by serum PSA concentration, prostate
cancer risk was decreased in finasteride and alpha-blocker users
with PSAX4ngml
 1 (the cut-off value for screen-positive test, i.e.,
indication for prostate biopsy; Table 4). The point estimate was
lower among finasteride users, but the confidence intervals
overlap. The decreased risk was driven by the lower incidence of
screen-detected tumours among these men. Risk of interval
cancers, that is, tumours diagnosed between the screening rounds,
was not significantly affected in finasteride users. However, among
alpha-blocker users with PSA below 4ngml
 1, the risk of interval
cancer was increased (HR 2.46; 95% CI 1.21–5.00).
DISCUSSION
In our cohort study within the screening arm of the Finnish
Prostate Cancer Screening Trial we found a reduced risk of low-
grade prostate cancer among finasteride users, among whom an
increased risk of high-grade cancers was seen among long-term
users. These findings confirm previous findings on this topic, but
provide wider generalisability than the Prostate Cancer Preven-
tion Trial, and improved internal validity compared with non-
randomised studies due to comprehensive and systematic case
ascertainment. Alpha-blocker usage generally did not affect
incidence, but some evidence for a decreased risk of high-grade
tumours was observed.
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yAvailability of comprehensive and detailed information on
medication purchases from the SII prescription database allowed
us to evaluate BPH medication usage accurately and in an
unbiased fashion. Finasteride, tamsulosin and alfuzosin were
available in Finland only through the physician’s prescription
during the study period, so their purchase is comprehensively
documented by the prescription database.
Our finding of a decreased risk of low-grade tumours among
finasteride users is similar with the results from the Prostate
Cancer Prevention Trial (Thompson et al, 2003). However, a major
limitation of our study in comparison to PCPT is that this is a
non-experimental study without any intervention related to BPH
medication, whereas PCPT was a randomised clinical trial. Due to
lack of random allocation, our results are, therefore, more prone to
systematic differences between men with or without BPH. In our
study, finasteride was prescribed for treatment of symptomatic
BPH, whereas men eligible for PCPT were free of LUTS and had
PSA of 3ngml
 1 or less (Thompson et al, 2003). Therefore, our
study population was more representative of the general popula-
tion with BPH in terms of prostate volume and PSA.
The PCPT study protocol included offering an end-of-study
prostate biopsy for all willing participants regardless of symptoms
or PSA level, resulting in high prostate tumour incidence with
obvious potential for overdiagnosis of indolent tumours but also
reducing possibility of detection bias (Thompson et al, 2003). In
our study, all men were screened and only screen-positive men
(PSA 4ngml
 1 or higher or PSA between 3 and 4ngml
 1 and
proportion of free PSA below 16%) underwent biopsy. Thus, our
study shows that the protective effect also applies to men using
finasteride for treatment of BPH and attending standard urological
care, a conclusion supported by a previous case–control study
(Irani et al, 2002). Unlike PCPT, we did not observe a significant
decrease in overall risk among finasteride users, although the
relative risk reduction in our study (22%) was close to that
reported in the PCPT (25%). However, among the biopsied
(screen-positive) men, the overall risk decrease was also significant
in our study. It should be noted that the average duration and
cumulative amount of finasteride usage was lower in our study
than in the PCPT.
In this study, finasteride users had symptomatic BPH, and
confounding by indication could affect the results, if BPH affects
the risk of prostate cancer or additional testing in the clinical
setting would affect prostate cancer detection. In this case, a
positive association between BPH and prostate cancer and further
PSA tests would be expected to increase detection. In our study,
the contrary was observed, so BPH as indication for finasteride use
cannot account for our findings. Unlike the PCPT trial (Thompson
et al, 2003), we did not observe overall risk increase for high-grade
prostate tumours among finasteride users. However, the risk was
increased among long-term users, although no dose dependence
between cumulative dose or duration of finasteride use and risk of
high-grade cancer was observed. Later analyses of the PCPT results
Table 1 Characteristics of users and non-users of finasteride and alpha-blockers in the Finnish Prostate Cancer Screening Trial
Finasteride usage Alpha-blocker usage
a
Yes No Yes No
Characteristics:
Participants (n) 1754 21566 3848 19472
Age at randomisation (years) No. of men (% of total) No. of men (% of total)
55 261 (3.5) 7295 (96.5) 790 (10.5) 6766 (89.5)
59 427 (6.9) 5804 (93.1) 998 (16.0) 5233 (84.0)
63 476 (9.2) 4674 (90.8) 1025 (19.9) 4125 (80.1)
67 590 (13.5) 3793 (86.5) 1035 (23.6) 3348 (76.4)
Prevalence of family history of prostate
cancer (%)
b
0.3 0.3 0.4 0.3
Mean no. of screening rounds attended 2.0 1.9 2.0 1.9
Geometric mean of PSA (95% CI)
c 1.58 (0.24–11.05) 1.22 (0.27–7.72) 1.60 (0.28–9.46) 1.22 (0.26–7.67)
Po0.001
d Po0.001
Cumulative amount of medication use
e Non-users 1.22 (0.27–7.72) Non-users 1.22 (0.26–7.67)
1st quartile 1.95 (0.31–12.94) — 1.54 (0.26–8.64) —
2nd quartile 1.72 (0.19–9.56) — 1.66 (0.19–9.07) —
3rd quartile 1.49 (0.23–8.94) — 1.58 (0.29–9.58) —
4th quartile 1.31 (0.17–1.25) — 1.80 (0.36–11.66) —
Geometric mean of % free PSA (95% CI)
c 22.37 (9.49–48.36) 26.48 (10.40–52.80) 25.26 (10.56–50.96) 26.43 (10.30–52.80)
Po0.001 Po0.001
Cumulative amount of medication use
e Non-users 1.22 (0.27–7.72) Non-users 1.22 (0.26–7.67)
1st quartile 22.87 (10.96–45.40) — 25.26 (10.50–50.99) —
2nd quartile 22.67 (9.13–47.26) — 24.66 (9.90–47.47) —
3rd quartile 21.22 (9.35–48.59) — 25.36 (10.85–54.85) —
4th quartile 21.12 (7.75–43.57) — 25.76 (10.76–52.53) —
Men attending the third screening round (N¼3130)
Median body mass index 26.7 26.2 26.6 26.2
P¼0.032 P¼0.035
Median prostate volume (ml)
f 49 36 42 36
Po0.001 Po0.001
aIncludes users of tamsulosin and alfuzosin.
bFather, brother or son diagnosed with prostate cancer prior to initiation of the Finnish Prostate Cancer Screening Trial.
cAge-standardised values.
dP estimated using Man–Whitney U-test.
eQuartiles for finasteride users : 28–180 doses (1st quartile), 181–398 doses (2nd quartile), 399–1086
doses (3rd quartile), 1087 doses or more (4th quartile); for alpha-blockers: 10–60 doses (1st quartile), 61–180 doses (2nd quartile), 181–629 doses (3rd quartile) and
630 doses or more (4th quartile).
fAs measured by a urologist on a transrectal ultrasound examination.
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yhave shown that the observed higher proportion of high-grade
cancers in finasteride-treated men is due to detection bias caused
by decreased prostate volume, increased sensitivity of PSA to
detect prostate cancer and altered tumour grading in finasteride
users (Thompson et al, 2006; Lucia et al, 2007; Pinsky et al, 2008).
This effect could also have caused the slightly increased incidence
of high-grade tumours in our study.
Use of alpha-blockers tamsulosin and alfuzosin had no effect
on overall risk, but there was some indication of a reduced risk
of high-grade tumours. Previously, quinazoline-derived alpha-
Table 2 Hazard ratio for prostate cancer by amount and duration of use of finasteride and by prostate cancer stage and grade, Finnish Prostate Cancer
Screening Trial









cases HR (95% CI)
c
No. of
cases HR (95% CI)
No. of
cases HR (95% CI)
No. of
cases HR (95% CI)
No. of
cases HR (95% CI)
Finasteride
Non-users 1507 Reference 1139 Reference 338 Reference 1364 Reference 143 Reference
All users 87 0.87 (0.63–1.19) 55 0.59 (0.38–0.91) 26 1.33 (0.77–2.30) 81 0.89 (0.65–1.24) 6 0.55 (0.14–2.24)
Cumulative quantity of finasteride use (daily doses)
d
28–180 34 1.34 (0.74–2.42) 24 0.80 (0.33–1.92) 6 1.17 (0.29–4.74) 32 1.32 (0.70–2.46) 2 1.48 (0.21–10.68)
181–398 21 0.91 (0.50–1.65) 14 0.76 (0.36–1.60) 5 0.79 (0.20–3.20) 19 1.00 (0.55–1.81) 2 —
399–1086 17 0.57 (0.27–1.19) 13 0.64 (0.29–1.43) 4 0.37 (0.05–2.68) 17 0.61 (0.29–1.28) 0 —
X1087 15 0.82 (0.47–1.46) 4 0.28 (0.09–0.87) 11 2.49 (1.27–4.89) 13 0.81 (0.45–1.48) 2 0.96 (0.13–6.94)
Ptrend
e 0.204 0.009 0.114 0.275 0.415
Years of finasteride use
d
1 41 0.89 (0.5–1.48) 30 0.62 (0.31–1.24) 7 0.57 (0.14–2.32) 39 0.91 (0.53–1.54) 2 0.66 (0.09–4.71)
2 19 0.96 (0.50–1.85) 13 0.84 (0.38–1.88) 5 1.02 (0.25–4.13) 19 1.03 (0.53–1.99) 0 —
3–4 11 0.72 (0.39–1.35) 7 0.48 (0.20–1.16) 4 1.60 (0.66–3.91) 10 0.70 (0.36–1.34) 2 1.10 (0.15–7.94)
44 16 1.00 (0.47–2.11) 5 0.40 (0.10–1.61) 10 2.61 (1.06–6.45) 13 1.07 (0.51–2.28) 2 —
Ptrend 0.411 0.019 0.057 0.524 0.429
aMen with T1N0/XM0/X and T2N0/XM0/X tumours combined.
bMen with stage T3N0/XM0/X,T 4N0/XM0/X,T 1–4N1M0 or T1–4N0–1M1 tumours combined.
cFrom Cox
proportional hazard regression adjusted for age, family history of prostate cancer, use of alpha-blockers, number of PSA screens and time period of screening (before or after year
2000).
dStratification in quartiles of cumulative quantity/duration of finasteride use.
eEstimated by including cumulative dose (DDDs) or duration (years) of medication use into
Cox regression model as a continuous covariate. All statistical trends are inverse, i.e., indicating a decreased risk with larger amount of medication use.
Table 3 Hazard ratio for prostate cancer by amount and duration of use of alpha-blockers and by prostate cancer stage and grade, Finnish Prostate
Cancer Screening Trial









cases HR (95% CI)
c
No. of
cases HR (95% CI)
No. of
cases HR (95% CI)
No. of
cases HR (95% CI)
No. of
cases HR (95% CI)
Alpha-blockers
Non-users 1399 Reference 1041 Reference 330 Reference 1262 Reference 137 Reference
All users 195 1.05 (0.85–1.31) 153 1.20 (0.94–1.52) 34 0.55 (0.31–0.96) 183 1.09 (0.87–1.36) 12 0.70 (0.28–1.73)
Cumulative quantity of alpha-blockers use (daily doses)
d
10–60 77 1.25 (0.83–1.87) 62 1.65 (1.09–2.49) 12 0.21 (0.03–1.52) 70 1.27 (0.83–1.93) 7 1.17 (0.29–4.72)
61–180 46 1.00 (0.64–1.56) 35 0.84 (0.48–1.49) 8 0.95 (0.39–2.30) 44 0.99 (0.62–1.58) 2 1.14 (0.28–4.64)
181–629 39 1.11 (0.75–1.64) 30 1.21 (0.77–1.88) 8 0.64 (0.24–1.72) 37 1.16 (0.78–1.73) 2 0.54 (0.08–3.86)
X630 33 0.89 (0.59–1.36) 26 1.12 (0.72–1.75) 6 0.40 (0.13–1.25) 32 0.96 (0.64–1.46) 1 —
Ptrend
e 0.975 0.345 0.053 0.700 0.230
Years of alpha-blockers use
d
1 111 1.00 (0.73–1.38) 86 1.08 (0.75–1.55) 19 0.60 (0.27–1.35) 102 1.00 (0.72–1.39) 9 1.10 (0.41–2.99)
2 43 1.46 (1.00–2.15) 36 1.67 (1.09–2.56) 5 0.60 (0.19–1.89) 42 1.53 (1.03–2.26) 2 0.70 (0.10–5.01)
3–4 23 0.87 (0.55–1.37) 15 1.04 (0.63–1.70) 8 0.48 (0.15–1.52) 21 0.93 (0.59–1.47) 1 —
44 18 0.88 (0.42–1.86) 16 1.15 (0.51–2.60) 2 0.38 (0.05–2.73) 18 0.96 (0.45–2.03) 0 —
Ptrend 0.858 0.186 0.044 0.580 0.208
aMen with T1N0/XM0/X and T2N0/XM0/X tumours combined.
bMen with stage T3N0/XM0/X,T 4N0/XM0/X,T 1–4N1M0 or T1–4N0–1M1 tumours combined.
cFrom Cox
proportional hazard regression adjusted for age, family history of prostate cancer, use of alpha-blockers, number of PSA screens and time period of screening (before or after year
2000).
dStratification in quartiles of cumulative quantity/duration of alpha-blocker use.
eEstimated by including cumulative dose (DDDs) or duration (years) of medication use into
Cox regression model as a continuous covariate. All statistical trends are inverse, i.e., indicating a decreased risk with larger amount of medication use.
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yblockers, terazosin and doxazosin, have been reported to inhibit
prostate cancer cell growth and reduce incidence (Kyprianou and
Benning, 2000; Benning and Kyprianou, 2002; Harris et al, 2007).
Our results suggest that tamsulosin and alfuzosin could have
similar effects but this aspect needs further research.
PCPT reported decreased serum PSA concentrations in finaster-
ide users as compared with non-users (Etzioni et al, 2005). In
our study, instead, serum PSA was increased in both finasteride
and alpha-blocker users. Odds of having serum PSA exceeding
the prostate biopsy cut-point (4ngml
 1) was not decreased,
but conversely increased in finasteride users (OR 2.37; 95% CI
2.13–2.64). This is due to the fact that in our study these medi-
cations were used for BPH treatment and men using them are not
comparable with non-users. Therefore, these differences reflect the
effect of BPH, and not medications. However, the PSA concentra-
tion tended to decrease with increasing cumulative amount of
finasteride use, although the geometric mean PSA remained above
non-users even among men in the highest quartile of finasteride
use (1087 doses or more), though the confidence intervals were
wide (Table 1). A similar association was observed with increasing
duration of finasteride use (results not shown). For alpha-blockers,
the geometric mean PSA was constantly higher among users than
non-users with no decrease by duration or amount of use. The
decrease in the proportion of free PSA was more pronounced in
finasteride users and increased in relation with amount and
duration of medication use, probably reflecting its effect on
proportion of free PSA in long-term use, as such relation was not
observed in alpha-blocker users.
Both finasteride and alpha-blocker use was associated with a
decreased risk of screen-detected tumours among screen-positive
men. As the risk decrease was observed among users of both drug
groups, it may be due to the underlying disease, BPH. PSA eleva-
tion in men with LUTS (medication users) is often caused by
prostate enlargement, whereas in men with no such symptoms
(medication non-users) PSA increase is more commonly caused
by a prostate cancer. Alpha-blocker users, whose PSA was below
4ngml
 1, were at increased risk between the screening rounds.
This finding is consistent with our results from the previous case–
control study (Murtola et al, 2007) and may reflect a similar
mechanism. The Finnish guideline for clinical management of BPH
recommends using alpha-blockers if a man has significant LUTS
but no prostate enlargement (Finnish Medical Society Duodecim).
Symptoms lead to clinical examinations and thus possibly to
diagnosis despite the negative screening test. Additionally, men
with significant LUTS may undergo transurethral resection of the
prostate, in which incidental prostate cancer is a common finding
(Merrill and Wiggins, 2002). This would lead to a bias of greater
cancer detection in alpha-blocker users but not in finasteride
users, as finasteride reduces the need for surgical management of
BPH (Roehrborn et al, 2004).
We were able to control the confounding caused by age
and familial predisposition (Crawford, 2003) in the analysis.
Confounding by ethnicity (Crawford, 2003) is likely minimal
due to the homogeneity of the Finnish population with over 98
percent of the population being of Finnish ancestry
(Statistics Finland). Additionally, we had information on prostate
volume and BMI for a proportion of our study population.
Adjustment for these variables did not materially affect the
results.
Our study has some limitations. The number of stage T3, stage
T4, lymph node-positive or metastatic tumours was small in our
study population of screened men, limiting our inference
concerning the risk of advanced cancer. Similarly, we could not
analyse mortality among finasteride users due to the small number
of deaths.
We did not have information on less established prostate cancer
risk factors such as dietary patterns or nutrient intake (such as
selenium or vitamin E). Medication users may be more health
conscious than non-users, and follow a healthier diet, which could
have reduced the incidence in medication users.
Some exposure misclassification was likely caused by the fact that
the cohort follow-up started in 1996 at the earliest, though finasteride
was licensed in Finland in 1992. Additionally, SII does not reimburse
finasteride prescribed for treatment of androgenic alopecia, and thus
we did not have information on finasteride use for this indication.
Therefore, some of the finasteride users likely have longer history of
use than appeared in our study, a bias that may have weakened the
observed association with prostate cancer risk.
The decreased risk among finasteride users in a cohort
of men participating in the Finnish Prostate Cancer Screening
Trial suggest that finasteride has a clinically significant
preventive effect against low-grade tumours also when used for
treatment of symptomatic benign prostatic hyperplasia. Future
research should aim to evaluate whether finasteride can reduce
mortality.
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Table 4 Hazard ratio for screen-detected and interval prostate cancer among finasteride and alpha-blocker users, stratified by serum PSA level and serum
PSA, Finnish Prostate Cancer Screening Trial




(users/non-users) HR (95% CI)
a No. of cases HR (95% CI) No. of cases HR (95% CI)
Finasteride
Serum PSAo4 19/214 0.87 (0.43–1.76) 5/134 0.64 (0.23–1.79) 14/80 1.26 (0.48–3.31)
Serum PSAX4 68/1293 0.62 (0.46–0.83) 46/1084 0.61 (0.44–0.84) 22/209 0.49 (0.23–1.06)
Alpha-blockers
Serum PSAo4 48/185 1.75 (1.08–2.82) 20/119 1.40 (0.73–2.68) 28/66 2.46 (1.21–5.00)
Serum PSAX4 147/1214 0.72 (0.58–0.90) 97/1033 0.66 (0.51–0.84) 50/181 1.06 (0.64–1.73)
aFrom Cox proportional hazard regression adjusted for age, family history of prostate cancer, finasteride or alpha-blocker use, number of PSA screens and time period of
screening (before or after year 2000).
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